Recombinant human erythropoietin promotes the acquisition of a malignant phenotype in head and neck squamous cell carcinoma cell lines in vitro

BMC Research Notes

Volumn 4, Issue , 2011, Pages

  Abhold, Eric ^b   Rahimy, Elham ^b   Wang Rodriguez, Jessica ^a   Blair, Katherine J ^b   Yu, Michael A ^b   Brumund, Kevin T ^b   Weisman, Robert A ^b   Ongkeko, Weg M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83755228772     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-4-553     Document Type: Article

References (33)

1. Erythropoietin biology in cancer. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW, Clin Cancer Res 2006 12 2 332 339 10.1158/1078-0432.CCR-05-1771 16428469 (Pubitemid 43166118)
2. Antiapoptotic effects of erythropoietin in differentiated neuroblastoma SH-SY5Y cells require activation of both the STAT5 and AKT signaling pathways. Um M, Lodish HF, J Biol Chem 2006 281 9 5648 5656 16407271 (Pubitemid 43847662)
3. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Um M, Gross AW, Lodish HF, Cell Signal 2007 19 3 634 645 10.1016/j.cellsig.2006.08.014 17045782 (Pubitemid 46107815)
4. Breast cancer trial with erythropoietin terminated unexpectedly. Leyland-Jones B, Lancet Oncol 2003 4 8 459 460 10.1016/S1470-2045(03)01163-X 12901958 (Pubitemid 37009952)
5. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Henke M, Laszig R, Rübe C, Schäfer U, Haase K, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H, Lancet 2003 362 9392 1255 1260 10.1016/S0140-6736(03)14567-9 14575968 (Pubitemid 37324251)
6. FDA Briefing Document. http://www.fda.gov/ohrms/dockets/ac/08/briefing/ 2008-4345b2-01-FDA.pdf
7. Venous thromboembolism and mortality associated with recombinant erythropoietin and dabepoetin administration for the treatment of cancer-associated anemia. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, Barnato SE, Elverman KM, Courtney DM, McKoy JM, Edwards BJ, Tigue CC, Raisch DW, Yarnold PR, Dorr DA, Kuzel TM, Tallman MS, Trifilio SM, West DP, Lai SY, Henke, JAMA 2008 299 8 914 924 10.1001/jama.299.8.914 18314434 (Pubitemid 351397066)
8. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia. Kara O, Dizdar O, Altundag K, JAMA 2008 300 24 2855 author reply 2855-2857 19109113
9. Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A, Ferris RL, Grandis JR, Oncogene 2005 24 27 4442 4449 10.1038/sj.onc.1208635 15856028 (Pubitemid 40961767)
10. Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G, Verma A, Neoplasia 2005 7 5 537 543 10.1593/neo.04685 15967106 (Pubitemid 40791872)
11. Erythropoietin promotes MCF-7 breast cancer cell migration by an ERK/mitogen-activated protein kinase-dependent pathway and is primarily responsible for the increase in migration observed in hypoxia. Lester RD, Jo M, Campana M, Gonias SL, J Biol Chem 2005 280 47 39273 39277 10.1074/jbc.M509446200 16207704 (Pubitemid 41713881)
12. Anti-Epo receptor antibodies do not predict Epo receptor expression. Elliott S, Busse L, Bass MB, Lu H, Sarosi I, Sinclair AM, Spahr C, Um M, Van G, Begley CG, Blood 2006 107 1892 1895 10.1182/blood-2005-10-4066 16249375 (Pubitemid 43289368)
13. Erythropoietin and erythropoietin receptor expression in human cancer. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K, Verma A, Cancer Res 2001 61 3561 3565 11325818 (Pubitemid 32694960)
14. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment. Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C, Health Technol Assess 2007 11 13 1 202 17927921
15. Safety of erythropoietin-stimulating agents (ESAs) in oncology. US Food and Drug Administration, http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4301b2-01-01-Amgen.pdf Accessed June 10, 2011
16. Loss of Chromosome Arm 18q with Tumor Progression in Head and Neck Squamous Cancer. Takebayashi S, Hickson A, Ogawa T, Jung K, Mineta H, Ueda Y, Grénman R, Fisher SG, Carey TE, Genes, Chromosomes Cancer 2004 41 2 145 154 10.1002/gcc.20066 15287027 (Pubitemid 39096740)
17. Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. Ribatti D, Marzullo A, Gentile A, Longo V, Nico B, Vacca A, Dammacco F, Histopathology 2007 50 5 591 596 10.1111/j.1365-2559.2007.02654.x 17394495 (Pubitemid 46495824)
18. Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality. Westphal G, Niederberger E, Blum C, Wollman Y, Knoch TA, Rebel W, Debus J, Friedrich E, Tumori 2002 88 2 150 159 12088257 (Pubitemid 34602189)
19. Erythropoietin receptor expression in human melanoma cells. Selzer E, Wacheck V, Kodym R, Schlagbauer-Wadl H, Schlegel W, Pehamberger H, Jansen B, Melanoma Res 2000 10 5 421 426 10.1097/00008390-200010000-00003 11095402
20. Studies on the role of recombinant human erythropoietin in the growth regulation of human nonhematopoietic tumor cells in vitro. Berdel WE, Oberberg D, Reufi B, Thiel E, Ann Hematol 1991 63 1 5 8 10.1007/BF01714953 1878424
21. Human recombinant erythropoietin (rEpo) has no effect on tumour growth or angiogenesis. Hardee ME, Kirkpatrick JP, Shan S, Snyder SA, Vujaskovic Z, Rabbani ZN, Dewhirst MW, Blackwell KL, Br J Cancer 2005 93 12 1350 1355 10.1038/sj.bjc.6602846 16288305 (Pubitemid 41752861)
22. Expression of erythropoietin and its receptor in neuroblastomas. Sartelet H, Fabre M, Castaing M, Bosq J, Racu I, Lagonotte E, Scott V, Lecluse Y, Barette S, Michiels S, Vassal G, Cancer 2007 110 5 1096 1106 10.1002/cncr.22879 17647284 (Pubitemid 47312876)
23. Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Batra S, Perelman N, Luck LR, Shimada H, Malik P, Lab Invest 2003 83 10 1477 1487 10.1097/01.LAB.0000090156.94795.48 14563949 (Pubitemid 37267831)
24. Functional erythropoietin autocrine loop in melanoma. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X, Am J Pathol 2005 166 3 823 830 10.1016/S0002-9440(10)62303-6 15743794 (Pubitemid 40315639)
25. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A, Am J Pathol 2003 162 6 1789 1806 10.1016/S0002-9440(10)64314-3 12759237 (Pubitemid 36613038)
26. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile J, Souhami L, Devic S, Chow TYK, Mol Cancer Ther 2004 3 12 1525 1533 15634645
27. Survival and invasiveness of astrocytomas promoted by erythropoietin. Mohyeldin A, Dalgard CL, Lu H, McFate T, Tait AS, Patel VC, Wong K, Rushing E, Roy S, Acs G, Verma J, J Neurosurg 2007 106 2 338 350 10.3171/jns.2007.106.2.338 17410721 (Pubitemid 46203166)
28. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Carvalho G, Lefaucheur C, Cherbonnier C, Métivier D, Chapel A, Pallardy M, Bourgeade MF, Charpentier B, Hirsch F, Kroemer G, Oncogene 2005 24 5 737 745 10.1038/sj.onc.1208205 15580299 (Pubitemid 40216083)
29. Recombinant erythropoietin differently affects proliferation of mesothelioma cells but not sensitivity to cisplatin and pemetrexed. Palumbo C, Battisti S, Carbone D, Albonici L, Alimandi M, Bei R, Modesti A, Cancer Chemother Pharmacol 2008 61 893 901 10.1007/s00280-007-0608-3 17922127 (Pubitemid 351302044)
30. Impact of erythropoietin on the effects of irradiation under hypoxia. Lo Nigro C, Maffi M, Fischel JL, Monteverde M, Catarsi P, Tonissi F, Lattanzio L, Riba M, Etienne-Grimaldi M, Formento P, Milano G, Merlano M, J Cancer Res Clin Oncol 2009 135 11 1615 1623 10.1007/s00432-009-0609-1 19499245
31. Induction of signalling in non-erythroid cells by pharmacological levels of erythropoietin. Dunlop EA, Percy MJ, Boland MP, Maxwell MP, Lappin TR, Neurodegener Dis 2006 3 1-2 94 100 10.1159/000092099 16909043 (Pubitemid 43760374)
32. Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells. Myklebust JH, Blomhoff HK, Rusten LS, Stokke T, Smeland EB, Exp Hematol 2002 30 9 990 1000 10.1016/S0301-472X(02)00868-8 12225790 (Pubitemid 35286615)
33. Erythropoietin activates the phosphoinositide 3-kinase/Akt pathway in human melanoma cells. Kumar SM, Yu H, Fong D, Acs G, Xu X, Melanoma Res 2006 16 4 275 283 10.1097/01.cmr.0000222594.60611.c3 16845323 (Pubitemid 44090171)